首页
Latest Findings on Polyketides/Non-ribosomal Peptides That Are Secondary Metabolites of Streptococcus mutans
-
摘要: 龋病是在以细菌为主的多因素影响下，牙体硬组织发生的慢性感染性疾病。变异链球菌被认为是引起龋病的主要病原体。次级代谢产物是由变异链球菌合成的一类小分子化合物，包括细菌素和聚酮/非核糖体肽。目前已发现的变异链球菌聚酮/非核糖体肽类次级代谢产物主要有mutanobactin、mutanocyclin和mutanofactin，分别由mub、muc和muf基因簇合成，参与细菌菌种间竞争、氧化应激、生物膜形成等多项生理活动。本文就变异链球菌3种主要聚酮/非核糖体肽类次级代谢产物mutanobactin、mutanocyclin和mutanofactin的合成、功能和调控等方面进行综述，为进一步研究变异链球菌致龋机制和龋病防治提供新的思路。Abstract: Dental caries is a chronic infectious disease that occurs in the hard tissue of teeth under the influence of multiple factors, among which bacteria being a key factor. Streptococcus mutans (S. mutans) is considered a major pathogen that causes caries. Secondary metabolites, including bacteriocins and polyketides/non-ribosomal peptides, are a class of small-molecule compounds synthesized by S. mutans. To date, polyketides/non-ribosomal peptides identified in S. mutans include mutanobactin, mutanocyclin, and mutanofactin, which are synthesized by the mub, muc, and muf biosynthetic gene clusters, respectively. These polyketides/non-ribosomal peptides play important roles in bacterial inter-species competition, oxidative stress, and biofilm formation. In this review, we provided an overview of the synthesis, function and regulation of three polyketides/non-ribosomal peptides of S. mutans, including mutanobactin, mutanocyclin, and mutanofactin, aiming to provide new insights into the cariogenic mechanism of S. mutans and to promote the better management of dental caries.
-
Key words:
- Dental caries /
- Streptococcus mutans /
- Secondary metabolites /
- Polyketides /
- Non-ribosomal peptides
-
图 1 Mutanobactin A、B、C、D的化学结构
Figure 1. Chemical structures of mutanobactin A, B, C, and D
图 2 Reutericyclin A、B、C和mutanocyclin的化学结构
Figure 2. Chemical structures of reutericyclin A, B, and C and mutanocyclin
-
[1] 陈冬茹, 林焕彩. 变异链球菌致龋机制研究新进展. 四川大学学报(医学版),2022,53(2): 208–213. doi: 10.12182/20220360508 [2] LEMOS J A, PALMER S R, ZENG L, et al. The biology of Streptococcus mutans. Microbiol Spectr,2019,7(1): 10.1128/microbiolspec.GPP3-0051-2018. doi: 10.1128/microbiolspec.GPP3-0051-2018 [3] RUIZ B, CHAVEZ A, FORERO A, et al. Production of microbial secondary metabolites: regulation by the carbon source. Crit Rev Microbiol,2010,36(2): 146–167. doi: 10.3109/10408410903489576 [4] 谢周杰, 张昭, 刘力伟, 等. 变形链球菌中的次级代谢产物及其在口腔生物被膜中的生态功能. 生物工程学报,2017,33(9): 1547–1554. doi: 10.13345/j.cjb.170046 [5] HEILBRONNER S, KRISMER B, BROTZ-OESTERHELT H, et al. The microbiome-shaping roles of bacteriocins. Nat Rev Microbiol,2021,19(11): 726–739. doi: 10.1038/s41579-021-00569-w [6] HAMADA S, OOSHIMA T. Inhibitory spectrum of a bacteriocinlike substance (mutacin) produced by some strains of Streptococcus mutans. J Dent Res,1975,54(1): 140–145. doi: 10.1177/00220345750540010801 [7] QI F, CHEN P, CAUFIELD P W. Purification and biochemical characterization of mutacin I from the group I strain of Streptococcus mutans, CH43, and genetic analysis of mutacin I biosynthesis genes. Appl Environ Microbiol,2000,66(8): 3221–3229. doi: 10.1128/AEM.66.8.3221-3229.2000 [8] NOVAK J, CAUFIELD P W, MILLER E J. Isolation and biochemical characterization of a novel lantibiotic mutacin from Streptococcus mutans. J Bacteriol,1994,176(14): 4316–4320. doi: 10.1128/jb.176.14.4316-4320.1994 [9] QI F, CHEN P, CAUFIELD P W. Purification of mutacin Ⅲ from group Ⅲ Streptococcus mutans UA787 and genetic analyses of mutacin III biosynthesis genes. Appl Environ Microbiol,1999,65(9): 3880–3887. doi: 10.1128/AEM.65.9.3880-3887.1999 [10] HILLMAN J D, NOVAK J, SAGURA E, et al. Genetic and biochemical analysis of mutacin 1140, a lantibiotic from Streptococcus mutans. Infect Immun,1998,66(6): 2743–2749. doi: 10.1128/IAI.66.6.2743-2749.1998 [11] MOTA-MEIRA M, LACROIX C, LAPOINTE G, et al. Purification and structure of mutacin B-Ny266: a new lantibiotic produced by Streptococcus mutans. FEBS Letters,1997,410(2/3): 275–279. doi: 10.1016/s0014-5793(97)00425-0 [12] YONEZAWA H, KURAMITSU H K. Genetic analysis of a unique bacteriocin, Smb, produced by Streptococcus mutans GS5. Antimicrob Agents Chemother,2005,49(2): 541–548. doi: 10.1128/AAC.49.2.541-548.2005 [13] ROBSON C L, WESCOMBE P A, KLESSE N A,et al. Isolation and partial characterization of the Streptococcus mutans type AⅡ lantibiotic mutacin K8. Microbiology (Reading),2007,153(Pt 5): 1631–1641. doi: 10.1099/mic.0.2006/003756-0 [14] QI F, CHEN P, CAUFIELD P W. The group I strain of Streptococcus mutans, UA140, produces both the lantibiotic mutacin I and a nonlantibiotic bacteriocin, mutacin Ⅳ. Appl Environ Microbiol,2001,67(1): 15–21. doi: 10.1128/AEM.67.1.15-21.2001 [15] HALE J D, TING Y T, JACK R W, et al. Bacteriocin (mutacin) production by Streptococcus mutans genome sequence reference strain UA159: elucidation of the antimicrobial repertoire by genetic dissection. Appl Environ Microbiol,2005,71(11): 7613–7617. doi: 10.1128/AEM.71.11.7613-7617.2005 [16] BALAKRISHNAN M, SIMMONDS R S, CARNE A, et al. Streptococcus mutans strain N produces a novel low molecular mass non-lantibiotic bacteriocin. FEMS Microbiol Lett,2000,183(1): 165–169. doi: 10.1111/j.1574-6968.2000.tb08952.x [17] XIE Z, OKINAGA T, NIU G, et al. Identification of a novel bacteriocin regulatory system in Streptococcus mutans. Molecular Microbiol,2010,78(6): 1431–1447. doi: 10.1111/j.1365-2958.2010.07417.x [18] MERRITT J, QI F. The mutacins of Streptococcus mutans: regulation and ecology. Mol Oral Microbiol,2012,27(2): 57–69. doi: 10.1111/j.2041-1014.2011.00634.x [19] WILLIAMS G J. Engineering polyketide synthases and nonribosomal peptide synthetases. Curr Opin Struct Biol,2013,23(4): 603–612. doi: 10.1016/j.sbi.2013.06.012 [20] KELLER N P. Fungal secondary metabolism: regulation, function and drug discovery. Nat Rev Microbiol,2019,17(3): 167–180. doi: 10.1038/s41579-018-0121-1 [21] PALAZZOTTO E, TONG Y, LEE S Y, et al. Synthetic biology and metabolic engineering of actinomycetes for natural product discovery. Biotechnol Adv,2019,37(6): 107366. doi: 10.1016/j.biotechadv.2019.03.005 [22] SUBHAN M, FARYAL R, MACREADIE I. Exploitation of aspergillus terreus for the production of natural statins. J Fungi (Basel),2016,2(2): 13. doi: 10.3390/jof2020013 [23] LI Y F, TSAI K J S, HARVEY C J B, et al. Comprehensive curation and analysis of fungal biosynthetic gene clusters of published natural products. Fungal Genet Biol,2016,89: 18–28. doi: 10.1016/j.fgb.2016.01.012 [24] SUSSMUTH R D, MAINZ A. Nonribosomal peptide synthesis-principles and prospects. Angew Chem Int Ed Engl,2017,56(14): 3770–3821. doi: 10.1002/anie.201609079 [25] DONIA M S, FISCHBACH M A. HUMAN MICROBIOTA. Small molecules from the human microbiota. Science,2015,349(6246): 1254766. doi: 10.1126/science.1254766 [26] BUKELSKIS D, DABKEVICIENE D, LUKOSEVICIUTE L, et al. Screening and transcriptional analysis of polyketide synthases and non-ribosomal peptide synthetases in bacterial strains from Krubera-Voronja cave. Front Microbiol,2019,10: 2149. doi: 10.3389/fmicb.2019.02149 [27] DONIA M S, CIMERMANCIC P, SCHULZE C J, et al. A systematic analysis of biosynthetic gene clusters in the human microbiome reveals a common family of antibiotics. Cell,2014,158(6): 1402–1414. doi: 10.1016/j.cell.2014.08.032 [28] WU C, CICHEWICZ R, LI Y, et al. Genomic island TnSmu2 of Streptococcus mutans harbors a nonribosomal peptide synthetase-polyketide synthase gene cluster responsible for the biosynthesis of pigments involved in oxygen and H2O2 tolerance. Appl Environ Microbiol,2010,76(17): 5815–5826. doi: 10.1128/AEM.03079-09 [29] WANG X, DU L, YOU J, et al. Fungal biofilm inhibitors from a human oral microbiome-derived bacterium. Org Biomol Chem,2012,10(10): 2044–2050. doi: 10.1039/c2ob06856g [30] ZVANYCH R, LUKENDA N, LI X, et al. Systems biosynthesis of secondary metabolic pathways within the oral human microbiome member Streptococcus mutans. Mol Biosyst,2015,11(1): 97–104. doi: 10.1039/c4mb00406j [31] JOYNER P M, LIU J, ZHANG Z, et al. Mutanobactin A from the human oral pathogen Streptococcus mutans is a cross-kingdom regulator of the yeast-mycelium transition. Org Biomol Chem,2010,8(24): 5486–5489. doi: 10.1039/c0ob00579g [32] PULTAR F, HANSEN M E, WOLFRUM S, et al. Mutanobactin D from the human microbiome: total synthesis, configurational assignment, and biological evaluation. J Am Chem Soc,2021,143(27): 10389–10402. doi: 10.1021/jacs.1c04825 [33] CHATTORAJ P, MOHAPATRA S S, RAO J L, et al. Regulation of transcription by SMU.1349, a TetR family regulator, in Streptococcus mutans. J Bacteriol,2011,193(23): 6605–6613. doi: 10.1128/JB.06122-11 [34] CHATTORAJ P, BANERJEE A, BISWAS S, et al. ClpP of Streptococcus mutans differentially regulates expression of genomic islands, mutacin production, and antibiotic tolerance. J Bacteriol,2010,192(5): 1312–1323. doi: 10.1128/JB.01350-09 [35] WANG Y, CAO W, MERRITT J, et al. Characterization of FtsH essentiality in Streptococcus mutans via genetic suppression. Front Genet,2021,12: 659220. doi: 10.3389/fgene.2021.659220 [36] RAINEY K, WILSON L, BARNES S, et al. Quantitative proteomics uncovers the interaction between a virulence factor and mutanobactin synthetases in Streptococcus mutans. mSphere,2019,4(5): e00429-19. doi: 10.1128/mSphere.00429-19 [37] WITTE G, HARTUNG S, BUTTNER K, et al. Structural biochemistry of a bacterial checkpoint protein reveals diadenylate cyclase activity regulated by DNA recombination intermediates. Mol Cell,2008,30(2): 167–178. doi: 10.1016/j.molcel.2008.02.020 [38] CHENG X, ZHENG X, ZHOU X, et al. Regulation of oxidative response and extracellular polysaccharide synthesis by a diadenylate cyclase in Streptococcus mutans. Environ Microbiol,2016,18(3): 904–922. doi: 10.1111/1462-2920.13123 [39] HAO T, XIE Z, WANG M, et al. An anaerobic bacterium host system for heterologous expression of natural product biosynthetic gene clusters. Nat Commun,2019,10(1): 3665. doi: 10.1038/s41467-019-11673-0 [40] TANG X, KUDO Y, BAKER J L, et al. Cariogenic Streptococcus mutans produces tetramic acid strain-specific antibiotics that impair commensal colonization. ACS Infect Dis,2020,6(4): 563–571. doi: 10.1021/acsinfecdis.9b00365 [41] TAO L, WANG M, GUAN G, et al. Streptococcus mutans suppresses filamentous growth of Candida albicans through secreting mutanocyclin, an unacylated tetramic acid. Virulence,2022,13(1): 542–557. doi: 10.1080/21505594.2022.2046952 [42] URANGA C, NELSON K E, EDLUND A, et al. Tetramic acids mutanocyclin and reutericyclin A, produced by streptococcus mutans strain b04sm5 modulate the ecology of anin vitro oral biofilm. Front Oral Health,2021,2: 796140. doi: 10.3389/froh.2021.796140 [43] BAKER J L, TANG X, LABONTE S, et al. mucG, mucH, and mucI modulate production of mutanocyclin and reutericyclins in Streptococcus mutans B04Sm5. J Bacteriol,2022,204(5): e0004222. doi: 10.1128/jb.00042-22 [44] LI Z R, SUN J, DU Y, et al. Mutanofactin promotes adhesion and biofilm formation of cariogenic Streptococcus mutans. Nat Chem Biol,2021,17(5): 576–584. doi: 10.1038/s41589-021-00745-2 [45] ALETI G, BAKER J L, TANG X, et al. Identification of the bacterial biosynthetic gene clusters of the oral microbiome illuminates the unexplored social language of bacteria during health and disease. mBio,2019,10(2): e00321-19. doi: 10.1128/mBio.00321-19 [46] GUO C J, CHANG F Y, WYCHE T P, et al. Discovery of reactive microbiota-derived metabolites that inhibit host proteases. Cell,2017,168(3): 517–526.e18. doi: 10.1016/j.cell.2016.12.021 [47] WALSH C T. The chemical versatility of natural-product assembly lines. Acc Chem Res,2008,41(1): 4–10. doi: 10.1021/ar7000414 [48] WANG H, FEWER D P, HOLM L, et al. Atlas of nonribosomal peptide and polyketide biosynthetic pathways reveals common occurrence of nonmodular enzymes. Proc Natl Acad Sci U S A,2014,111(25): 9259–9264. doi: 10.1073/pnas.1401734111 [49] JENKE-KODAMA H, SANDMANN A, MULLER R, et al. Evolutionary implications of bacterial polyketide synthases. Mol Biol Evol,2005,22(10): 2027–2039. doi: doi:10.1093/molbev/msi193 [50] LIU L, HAO T, XIE Z, et al. Genome mining unveils widespread natural product biosynthetic capacity in human oral microbe Streptococcus mutans. Sci Rep,2016,6: 37479. doi: 10.1038/srep37479 [51] PASCAL ANDREU V, AUGUSTIJN H E, Van Den BERG K, et al. BiG-MAP: an automated pipeline to profile metabolic gene cluster abundance and expression in microbiomes. mSystems,2021,6(5): e0093721. doi: 10.1128/mSystems.00937-21 [52] HANSEN M E, YASMIN S O, WOLFRUM S, et al. Total synthesis of mutanobactins a, b from the human microbiome: macrocyclization and thiazepanone assembly in a single step. Angew Chem Int Ed Engl,2022,61(28): e202203051. doi: 10.1002/anie.202203051 -
下载:
点击查看大图
图(3)
计量
- 文章访问数: 22
- HTML全文浏览量: 5
- PDF下载量: 7
- 被引次数: 0
